Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213333550> ?p ?o ?g. }
- W4213333550 endingPage "291" @default.
- W4213333550 startingPage "291" @default.
- W4213333550 abstract "Alternative strategies against multidrug-resistant (MDR) bacterial infections are suggested to clinicians, such as drug repurposing, which uses rapidly available and marketed drugs. We gathered a collection of MDR bacteria from our hospital and performed a phenotypic high-throughput screening with a 1280 FDA-approved drug library. We used two Gram positive (Enterococcus faecium P5014 and Staphylococcus aureus P1943) and six Gram negative (Acinetobacter baumannii P1887, Klebsiella pneumoniae P9495, Pseudomonas aeruginosa P6540, Burkholderia multivorans P6539, Pandoraea nosoerga P8103, and Escherichia coli DSM105182 as the reference and control strain). The selected MDR strain panel carried resistance genes or displayed phenotypic resistance to last-line therapies such as carbapenems, vancomycin, or colistin. A total of 107 compounds from nine therapeutic classes inhibited >90% of the growth of the selected Gram negative and Gram positive bacteria at a drug concentration set at 10 µmol/L, and 7.5% were anticancer drugs. The common hit was the antiseptic chlorhexidine. The activity of niclosamide, carmofur, and auranofin was found against the selected methicillin-resistant S. aureus. Zidovudine was effective against colistin-resistant E. coli and carbapenem-resistant K. pneumoniae. Trifluridine, an antiviral, was effective against E. faecium. Deferoxamine mesylate inhibited the growth of XDR P. nosoerga. Drug repurposing by an in vitro screening of a drug library is a promising approach to identify effective drugs for specific bacteria." @default.
- W4213333550 created "2022-02-24" @default.
- W4213333550 creator A5012670349 @default.
- W4213333550 creator A5027599868 @default.
- W4213333550 creator A5049856945 @default.
- W4213333550 creator A5087376371 @default.
- W4213333550 date "2022-02-22" @default.
- W4213333550 modified "2023-09-26" @default.
- W4213333550 title "In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria" @default.
- W4213333550 cites W1527987690 @default.
- W4213333550 cites W1965049677 @default.
- W4213333550 cites W1968064381 @default.
- W4213333550 cites W1972831716 @default.
- W4213333550 cites W1975734203 @default.
- W4213333550 cites W1982057684 @default.
- W4213333550 cites W1991471402 @default.
- W4213333550 cites W2005302698 @default.
- W4213333550 cites W2005644016 @default.
- W4213333550 cites W2011006965 @default.
- W4213333550 cites W2016932468 @default.
- W4213333550 cites W2018145311 @default.
- W4213333550 cites W2028416848 @default.
- W4213333550 cites W2033303729 @default.
- W4213333550 cites W2056935867 @default.
- W4213333550 cites W2070125649 @default.
- W4213333550 cites W2077200031 @default.
- W4213333550 cites W2078817197 @default.
- W4213333550 cites W2096864263 @default.
- W4213333550 cites W2128136074 @default.
- W4213333550 cites W2128764402 @default.
- W4213333550 cites W2135465392 @default.
- W4213333550 cites W2138804563 @default.
- W4213333550 cites W2139313512 @default.
- W4213333550 cites W2142314945 @default.
- W4213333550 cites W2142343447 @default.
- W4213333550 cites W2165699474 @default.
- W4213333550 cites W2274641573 @default.
- W4213333550 cites W2285665565 @default.
- W4213333550 cites W2323553120 @default.
- W4213333550 cites W2347102183 @default.
- W4213333550 cites W2394973522 @default.
- W4213333550 cites W2398161826 @default.
- W4213333550 cites W2436632334 @default.
- W4213333550 cites W2466195257 @default.
- W4213333550 cites W2467298486 @default.
- W4213333550 cites W2471953347 @default.
- W4213333550 cites W2489287057 @default.
- W4213333550 cites W2515460183 @default.
- W4213333550 cites W2528756787 @default.
- W4213333550 cites W2533325435 @default.
- W4213333550 cites W2555742204 @default.
- W4213333550 cites W2567225729 @default.
- W4213333550 cites W2580029513 @default.
- W4213333550 cites W2584128012 @default.
- W4213333550 cites W2592013065 @default.
- W4213333550 cites W2598479690 @default.
- W4213333550 cites W2619238214 @default.
- W4213333550 cites W2735733520 @default.
- W4213333550 cites W2750330993 @default.
- W4213333550 cites W2769224333 @default.
- W4213333550 cites W2782655889 @default.
- W4213333550 cites W2790866522 @default.
- W4213333550 cites W2791045633 @default.
- W4213333550 cites W2793160008 @default.
- W4213333550 cites W2883234304 @default.
- W4213333550 cites W2891497705 @default.
- W4213333550 cites W2895387828 @default.
- W4213333550 cites W2896659352 @default.
- W4213333550 cites W2897089888 @default.
- W4213333550 cites W2897109701 @default.
- W4213333550 cites W2898130317 @default.
- W4213333550 cites W2898380553 @default.
- W4213333550 cites W2904379741 @default.
- W4213333550 cites W2904382879 @default.
- W4213333550 cites W2911691098 @default.
- W4213333550 cites W2912318433 @default.
- W4213333550 cites W2913573831 @default.
- W4213333550 cites W2950560626 @default.
- W4213333550 cites W2959696744 @default.
- W4213333550 cites W2968048251 @default.
- W4213333550 cites W2978217661 @default.
- W4213333550 cites W2981715574 @default.
- W4213333550 cites W2982173191 @default.
- W4213333550 cites W3047197438 @default.
- W4213333550 cites W4210868540 @default.
- W4213333550 cites W4229696844 @default.
- W4213333550 cites W4245459803 @default.
- W4213333550 doi "https://doi.org/10.3390/antibiotics11030291" @default.
- W4213333550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35326755" @default.
- W4213333550 hasPublicationYear "2022" @default.
- W4213333550 type Work @default.
- W4213333550 citedByCount "4" @default.
- W4213333550 countsByYear W42133335502022 @default.
- W4213333550 countsByYear W42133335502023 @default.
- W4213333550 crossrefType "journal-article" @default.
- W4213333550 hasAuthorship W4213333550A5012670349 @default.
- W4213333550 hasAuthorship W4213333550A5027599868 @default.
- W4213333550 hasAuthorship W4213333550A5049856945 @default.